49
views
0
recommends
+1 Recommend
0 collections
    8
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Proceedings of the 2016 China Cancer Immunotherapy Workshop : Beijing, China. 25-26 June 2016

      abstract
      1 , , 2 , , 3 , , 2 , 3 , 3 , , 4 , , 5 , , 6 , , 7 , , 8 , , 9 , , 10 , , 11 , , 12 , 13 , 14 , 15 , , 16 , , 17 , , 18 , , 19 , , 20 , 20 , 20 , 20 , 20 , 20 , 20 , 20 , 20 , 20 , , 21 , , 22 , , 23 , , 24 , , 25 , , 26 , , 27 , , 28 , , 29
      Journal of Hematology & Oncology
      BioMed Central
      2016 China Cancer Immunotherapy Workshop
      25-26 June 2016

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Table of contents

          A1 Proceedings of 2016 China Cancer Immunotherapy Workshop, Beijing, China

          Bin Xue, Jiaqi Xu, Wenru Song, Zhimin Yang, Ke Liu, Zihai Li

          A2 Set the stage: fundamental immunology in forty minutes

          Zihai Li

          A3 What have we learnt from the anti-PD-1/PD-L1 therapy of advanced human cancer?

          Lieping Chen

          A4 Immune checkpoint inhibitors in lung cancer

          Edward B. Garon

          A5 Mechanisms of response and resistance to checkpoint inhibitors in melanoma

          Siwen Hu-Lieskovan

          A6 Checkpoint inhibitor immunotherapy in lymphoid malignancies

          Wei Ding

          A7 Translational research to improve the efficacy of immunotherapy in genitourinary malignancies

          Chong-Xian Pan

          A8 Immune checkpoint inhibitors in gastrointestinal malignancies

          Weijing Sun

          A9 What’s next beyond PD-1/PDL1?

          Yong-Jun Liu

          A10 Cancer vaccines: new insights into the oldest immunotherapy strategy

          Lei Zheng

          A11 Bispecific antibodies for cancer immunotherapy

          Delong Liu

          A12 Updates on CAR-T immunotherapy

          Michel Sadelain

          A13 Adoptive T cell therapy: personalizing cancer treatment

          Cassian Yee

          A14 Immune targets and neoantigens for cancer immunotherapy

          Rongfu Wang

          A15 Phase I/IIa trial of chimeric antigen receptor modified T cells against CD133 in patients with advanced and metastatic solid tumors

          Meixia Chen, Yao Wang, Zhiqiang Wu, Hanren Dai, Can Luo, Yang Liu, Chuan Tong, Yelei Guo, Qingming Yang, Weidong Han

          A16 Cancer immunotherapy biomarkers: progress and issues

          Lisa H. Butterfield

          A17 Shaping of immunotherapy response by cancer genomes

          Timothy A. Chan

          A18 Unique development consideration for cancer immunotherapy

          Wenru Song

          A19 Immunotherapy combination

          Ruirong Yuan

          A20 Immunotherapy combination with radiotherapy

          Bo Lu

          A21 Cancer immunotherapy: past, present and future

          Ke Liu

          A22 Breakthrough therapy designation drug development and approval

          Max Ning

          A23 Current European regulation of innovative oncology medicines: opportunities for immunotherapy

          Harald Enzmann, Heinz Zwierzina

          Related collections

          Author and article information

          Contributors
          xb@ccfdie.org
          xujq@cde.org.cn
          wenru.song@gmail.com
          zihai@musc.edu
          zihai@musc.edu
          lieping.chen@yale.edu
          egaron@mednet.ucla.edu
          shu-lieskovan@mednet.ucla.edu
          ding.wei@mayo.edu
          cxpan@ucdavis.edu
          sunw@upmc.edu
          yong-jun.liu@sanofi.com
          lzheng6@jhmi.edu
          delong_liu@nymc.edu
          m-sadelain@ski.mskcc.org
          cyee@mdanderson.org
          rwang3@tmhs.org
          hanwdrsw@sina.com
          butterfieldl@upmc.edu
          chant@mskcc.org
          wenru.song@gmail.com
          yuan_rui@hotmail.com
          bo.lu@jefferson.edu
          keliunih@yahoo.com
          ymcanning986@gmail.com
          harald.enzmann@bfarm.de
          Conference
          J Hematol Oncol
          J Hematol Oncol
          Journal of Hematology & Oncology
          BioMed Central (London )
          1756-8722
          13 October 2016
          13 October 2016
          2016
          : 9
          Issue : Suppl 1 Issue sponsor : Publication of this supplement was funded by the China Center for Food and Drug International Exchange (CCFDIE).
          : 104
          Affiliations
          [1 ]China Center for Food and Drug International Exchange (CCFDIE), Beijing, China
          [2 ]Center for Drug Evaluation (CDE) of the China Food and Drug Administration (CFDA), Beijing, China
          [3 ]Chinese American Hematologist and Oncologist Network (CAHON), New York, NY USA
          [4 ]Department of Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC USA
          [5 ]Yale University, New Haven, CT USA
          [6 ]David Geffen School of Medicine at UCLA, Los Angeles, CA USA
          [7 ]University of California at Los Angeles, Los Angeles, CA USA
          [8 ]Hematology, Mayo Clinic, Rochester, MN USA
          [9 ]Department of Internal Medicine and Urology, University of California Davis Comprehensive Cancer Center, Sacramento, CA USA
          [10 ]University of Pittsburgh Cancer Center, Pittsburgh, PA USA
          [11 ]Global R&D, Sanofi, Paris, France
          [12 ]Department of Oncology and Surgery, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland USA
          [13 ]Skip Viragh Center for Pancreatic Cancer, Johns Hopkins University School of Medicine, Baltimore, Maryland USA
          [14 ]Bloomberg-Kimmel Institute of Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, Maryland USA
          [15 ]Graduate Program in Cellular and Molecular Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland USA
          [16 ]New York Medical College and Westchester Medical Center, Valhalla, NY USA
          [17 ]Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY USA
          [18 ]Department of Melanoma, MD Anderson Cancer Center, Houston, TX USA
          [19 ]Houston Methodist Research Institute, Houston Methodist Hospital and Weill Cornell Medicine, New Haven, TX USA
          [20 ]Department of Molecule & Immunology/Bio-therapeutic Department, Chinese PLA General Hospital, Beijing, 100853 China
          [21 ]University of Pittsburgh, Pittsburgh, PA USA
          [22 ]Memorial Sloan Kettering Cancer Center, New York, NY USA
          [23 ]Chinese American Hematologist and Oncologist Network (CAHON), New York, NY USA
          [24 ]New Jersey Veteran’s Administration Medical Center, East Orange, NJ USA
          [25 ]Thomas Jefferson University Sidney Kimmel Medical College, Philadelphia, PA USA
          [26 ]Chinese-American Hematologist and Oncologist Network (CAHON), New York, NY USA
          [27 ]Chinese-American Hematologist and Oncologist Network (CAHON), New York, NY USA
          [28 ]Federal Institute for Drugs and Medical Devices, Kurt-Georg-Kiesinger-Allee 3, 53175 Bonn, Germany
          [29 ]Cancer Drug Development Forum - CDDF Headquarters, c/o ECCO - Avenue E. Mounier 83, B-1200 Brussels, Belgium
          Article
          322
          10.1186/s13045-016-0322-x
          5073990
          a4745f37-9553-46e9-ad2c-abff5eadeb0e
          © The Author(s). 2016

          Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

          2016 China Cancer Immunotherapy Workshop
          Beijing, China
          25-26 June 2016
          History
          Categories
          Meeting Abstracts
          Custom metadata
          © The Author(s) 2016

          Oncology & Radiotherapy
          Oncology & Radiotherapy

          Comments

          Comment on this article